Table 2 Clinico-pathological characteristics in relation to IHC expression of CD68 and CD163
CD68 | P value | CD163 | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 1 | 2 | 3 | ||||
Age category | < 45 years | 31% | 30% | 11% | 0.5 | 29% | 31% | 12% | 0.05* |
≥ 45 years | 10% | 11% | 7% | 8% | 9% | 11% | |||
Gender | Male | 10% | 19% | 8% | 0.5 | 9% | 14% | 14% | 0.02* |
Female | 31% | 22% | 10% | 28% | 26% | 9% | |||
HB category | < 10.5 g/dl | 17% | 13% | 6% | 0.6 | 16% | 30% | 10% | 0.17 |
≥ 10.5 g/dl | 24% | 28% | 12% | 21% | 27% | 13% | |||
WBCs category | < 15 × 109/l | 35% | 34% | 16% | 0.8 | 30% | 35% | 20% | 0.7 |
≥ 15× 109/l | 6% | 7% | 2% | 7% | 5% | 3% | |||
Albumin level | < 4 g/dl | 16% | 14% | 5% | 0.9 | 15% | 10% | 10% | 0.03* |
≥ 4 g/dl | 24% | 21% | 7% | ||||||
20% | 27% | 5% | |||||||
HCV virology | Negative | 35% | 34% | 14% | 0.4 | 32% | 34% | 20% | 0.9 |
Positive | 6% | 7% | 1% | 5% | 6% | 3% | |||
B symptoms | Absent | 23% | 15% | 8% | 0.2 | 23% | 16% | 7% | 0.04* |
Present | 18% | 16% | 10% | 14% | 24% | 16% | |||
Bulky disease | No | 40% | 37% | 12% | 0.005* | 36% | 37% | 16% | 0.005* |
Yes | 1% | 4% | 6% | 1% | 3% | 7% | |||
Histopathology subtype | LR | 4% | 7% | 1% | 0.5 | 5% | 4% | 3% | 0.86 |
MC | 21% | 18% | 7% | 16% | 21% | 9% | |||
NS | 16% | 16% | 10% | 16% | 15% | 11% | |||
Extra nodal disease | No | 34% | 25% | 14% | 0.07 | 29% | 27% | 17% | 0.55 |
Yes | 7% | 16% | 4% | 8% | 13% | 6% | |||
Stage | Limited | 14% | 4% | 3% | 0.02* | 13% | 6% | 2% | 0.02* |
Advanced | 27% | 37% | 15% | 24% | 34% | 21% | |||
IPS | < 3 | 30% | 23% | 7% | 0.04* | 25% | 27% | 8% | 0.02* |
≥ 3 | 11% | 18% | 11% | 12% | 13% | 15% | |||
ORR | CR/PR | 38% | 24% | 11% | 0.001* | 34% | 28% | 11% | 0.001* |
NO CR/PR | 3% | 17% | 7% | 3% | 12% | 12% | |||